Assess whether a CMC change is a comparability or a new product (4397d4)

Situation

FDA Response and Labeling work in a company with a CMC site change mid-review now turns on a CMC change is because a pediatric ethicist objecting to the proposed design put disproportionate reporting signal workbook in play. Clinical-development physician should say what disproportionate reporting signal workbook proves.

Decision

Clinical-development physician in a company with a CMC site change mid-review must choose A CMC change is a comparability / A new product using disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled FDA Response and Labeling process in a company with a CMC site change mid-review, given disproportionate reporting signal workbook.
• A pediatric ethicist objecting to the proposed design is the event in disproportionate reporting signal workbook that forces A CMC change is a comparability for clinical-development physician under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a FDA Response and Labeling program failure.
• Disproportionate reporting signal workbook cannot decide a CMC change is yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a pediatric ethicist objecting to the proposed design and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for clinical-development physician in a company with a CMC site change mid-review.